Table 3.
| Brand name | Indication | Global sales in 2017 | International Nonproprietary Name |
|---|---|---|---|
| Humira | Rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis | $18.4 billion | Adalimumab |
| Rituxan | Non-Hodgkins lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis | $9.2 billion | Rituximab |
| Enbrel | Rheumatoid arthritis, plaque psoriasis, psoriatic arthritis | $7.9 billion | Etanercept |
| Herceptin | HER2+ breast cancer | $7.4 billion | Trastuzumab |
| Avastin | Breast, colorectal, kidney, non-small-cell lung, glioblastoma, ovarian cancers | $7.1 billion | Bevacizumab |
| Remicade | Rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis | $7.1 billion | Infliximab |
| Lantus | Diabetes | $5.7 billion | Insulin glargine |
| Neulasta | Cancer chemotherapy | $4.7 billion | Pegfilgrastim |
| Avonex | Multiple sclerosis | $2.1 billion | Interferon beta-1a |
| Lucentis | Age-related macular degeneration | $1.5 billion | Ranibizumab |
HER2: human epidermal growth factor receptor 2.
a
Blockbusters are defined here as products with annual sales of more than $1 billion.